⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRD News
Opus Genetics, Inc. Common Stock
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
globenewswire.com
IRD
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IRD
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
globenewswire.com
IRD
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
globenewswire.com
IRD
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IRD
Opus Genetics to Participate in Upcoming Investment Conferences
globenewswire.com
IRD
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
globenewswire.com
IRD
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
globenewswire.com
IRD
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
globenewswire.com
IRD
Opus Genetics Announces $23 Million Registered Direct Offering
globenewswire.com
IRD